Share

August 2018; 8 (4) Research

Safety and efficacy of plasma exchange in pediatric transverse myelitis

Daniel K. Noland, Benjamin M. Greenberg
First published June 18, 2018, DOI: https://doi.org/10.1212/CPJ.0000000000000480
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
120

Share

Article Information

vol. 8 no. 4 327-330
DOI: 
https://doi.org/10.1212/CPJ.0000000000000480
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received April 9, 2017
  • Accepted April 2, 2018
  • First Published June 18, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Disclosures

    1. Daniel K. Noland, MD and
    2. Benjamin M. Greenberg, MD, MHS
  1. Daniel K. Noland, MD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. 50% of my time is spent doing clinical apheresis, the treatment on which this study focuses. However, practice at this institution will not change as the conclusions are already followed.

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Benjamin M. Greenberg, MD, MHS
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Transverse Myelitis Association, funding for travel

    Editorial Boards:

    1. NONE

    Patents:

    1. Dr. Greenberg has filed patents on the use of antibody suppression in multiple sclerosis

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Novartis, Alexion, EMD Serono

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Medimmune, Chugai, Medday, Genentech

    Research Support, Government Entities:

    1. NIH RO1 NS071463, Co-investigator 2012-14

    Research Support, Academic Entities:

    1. Unviersity of Texas Southwestern

    Research Support, Foundations and Societies:

    1. Guthy Jackson Foundation, PCORI, Transverse Myelitis Association, National MS Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Departments of Pathology (DKN), Neurology and Neurotherapeutics (BMG), and Pediatrics (BMG), The University of Texas Southwestern Medical Center, Dallas; and Children's Health Dallas (DKN, BMG), TX.
  1. Correspondence
    Dr. Greenberg Benjamin.Greenberg{at}utsouthwestern.edu or Dr. Noland Daniel.Noland{at}childrens.com
View Full Text

Article usage

Article usage: June 2018 to July 2019

AbstractFullPdfSource
Jun 20189603Highwire
Jul 201814205Highwire
Aug 20185693528Highwire
Sep 20186743117Highwire
Oct 20184793112Highwire
Nov 20185322214Highwire
Dec 20186272211Highwire
Jan 201913754Highwire
Feb 2019102710Highwire
Mar 20195212Highwire
Apr 20194932Highwire
May 20197433Highwire
Jun 20193413Highwire
Jul 20195226Highwire

Cited By...

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.cp.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on The Nerve!

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate The Nerve! Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me